Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -1.20%73 Debt-to-EBITDA is 0.15 as of Mar. 2026, which is 42% below its 10-year median of 0.26. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT768.07 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 478 Medical Devices & Instruments companies, Pharma Aids ranks better than 87.03% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pharma Aids's Debt-to-EBITDA or its related term are showing as below:
DHA:PHARMAID'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.26 Max: 0.72
Current: 0.15
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pharma Aids was 0.72. The lowest was 0.00. And the median was 0.26.
DHA:PHARMAID's Debt-to-EBITDA is ranked better than 87.03% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs DHA:PHARMAID: 0.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pharma Aids Debt-to-EBITDA Related Terms
Pharma Aids Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pharma Aids's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Pharma Aids (DHA:PHARMAID) has a Debt-to-EBITDA of 0.15 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Aids. This is 42% below median its historical median of 0.26. According to the industry distribution chart, Pharma Aids ranks #62 out of 478 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Pharma Aids' Debt-to-EBITDA too high?
Pharma Aids' current Debt-to-EBITDA of 0.15 is 42% below median its 10-year median of 0.26. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.65. Pharma Aids' value of 0.15 is 90.9% below this industry median. Based on the distribution chart, Pharma Aids ranks #62 out of 478 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #62 out of 478 companies for Debt-to-EBITDA. This places Pharma Aids in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.65. Pharma Aids' value of 0.15 is 90.9% below this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 1.65, Pharma Aids has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current Debt-to-EBITDA of 0.15 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Aids. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current Debt-to-EBITDA is 0.15, which is 42% below median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT768.07, compared to a current price of BDT584.20 — trading 23.9% below its estimated fair value. The current Debt-to-EBITDA is 0.15, which is 42% below median its 10-year median of 0.26 and 90.9% below the Medical Devices & Instruments industry median of 1.65. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Debt-to-EBITDA is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT584.20 is trading 23.9% below its estimated GF Value™ of BDT768.07.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Debt-to-EBITDA: 0.15 (42% below median its 10-year median of 0.26)
GF Value™: BDT768.07 vs. price of BDT584.20 (23.9% below fair value)
Industry Position: 90.9% below the Medical Devices & Instruments median (#62 of 478)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
